ストックスクリーナーアプリを入手
3.11
1.58%
-0.05
アフターアワーズ：
3.26
0.15
+4.82%
前日終値:
$3.16
開ける：
$3.24
24時間の取引高:
91,919
Relative Volume:
1.00
時価総額：
$8.82M
収益：
-
当期純損益:
$-22.01M
株価収益率:
-0.4712
EPS:
-6.6
ネットキャッシュフロー:
$-18.31M
1週間 パフォーマンス:
-3.42%
1か月 パフォーマンス:
+22.92%
6か月 パフォーマンス:
-43.86%
1年 パフォーマンス:
-75.04%
1日の値動き範囲:
$3.05
$3.3601
1週間の範囲:
$3.04
$3.90
52週間の値動き範囲:
$1.39
$13.02
Vaccinex Inc Stock (VCNX) Company Profile
VCNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| VCNX | 3.11 | 8.82M | 0 | -22.01M | -18.31M | -6.60 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-09-23 | ダウングレード | BTIG Research | Buy → Neutral |
| 2018-09-04 | 開始されました | Ladenburg Thalmann | Buy |
Vaccinex Inc (VCNX) 最新ニュース
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Vaccinex Reports Promising Alzheimer's Drug Data, Raises $8.35M Amid Financial Challenges | VCNX Stock News - StockTitan
ARMISTICE CAPITAL, LLC Acquires Shares in Vaccinex Inc - GuruFocus.com
Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartzy
Latest Company News - Investing.com
Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com Canada
Vaccinex inks multiple antibody discovery deals using ActivMAb - Investing.com India
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewswire
Vaccinex Lands Major Pharma Deals: Amgen, Merck Partner on Breakthrough Antibody Tech | VCNX Stock News - StockTitan
Vaccinex Reports Improved Immunity Correlating with - GlobeNewswire
VCNXVaccinex, Inc. Latest Stock News & Market Updates - StockTitan
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting - GlobeNewswire
Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success | VCNX Stock News - StockTitan
Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Canada
Vaccinex reports progress in Alzheimer's treatment study - Investing.com India
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain - Nasdaq
Vaccinex stock tanks 40% despite positive Alzheimer’s study update - MSN
Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Barchart
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 - GlobeNewswire
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com
Vaccinex faces potential Nasdaq delisting over equity shortfall - Investing.com India
BTIG Research’s latest rating for VCNX stock - Knox Daily
Vaccinex faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Company’s Banking Shares: Up -90.42% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Post-Trade Analysis: Vaccinex Inc (VCNX) Slides -27.92, Closing at 1.73 - The Dwinnex
Vaccinex stock hits 52-week low at $2.98 amid market challenges - Investing.com
Vaccinex stock hits 52-week low at $4.17 amid sharp annual decline - Investing.com Canada
VSME’s price-to-free cash flow ratio: What it means for investors - US Post News
Short Interest in Victory Square Technologies Inc. (OTCMKTS:VSQTF) Declines By 79.4% - Defense World
Viemed Healthcare, Inc. (NASDAQ:VMD) Shares Purchased by Victory Capital Management Inc. - Defense World
WUXI BIO Buys back ~3.32M Shrs for ~$42.55M Ytd - AASTOCKS.com
Vaxcyte Inc (PCVX) receives a Buy rating from Mizuho - Knox Daily
Victrex plc (LON:VCT) Insider Jane Toogood Acquires 508 Shares - MarketBeat
Victrex Director Buys Shares, Signals Confidence - TipRanks
Bank of New York Mellon Corp Boosts Stock Holdings in Viemed Healthcare, Inc. (NASDAQ:VMD) - Defense World
StockNews.com Initiates Coverage on Vector Group (NYSE:VGR) - Defense World
VICR Investors Have Opportunity to Lead Vicor Corporation Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
The Gross Law Firm Reminds Vicor Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 23, 2024VICR - PR Newswire
Victory Capital Management Inc. Has $496,000 Stock Holdings in Zymeworks Inc. (NYSE:ZYME) - Defense World
Rhumbline Advisers Has $1.01 Million Position in V2X, Inc. (NYSE:VVX) - Defense World
Choreo LLC Takes Position in Vector Group Ltd. (NYSE:VGR) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
VICR FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, - GlobeNewswire
First Eagle Investment Management LLC Purchases 2,067 Shares of V2X, Inc. (NYSE:VVX) - Defense World
Vaccinex issues new warrants, secures $6.2 million in funding - Investing.com
Victory Capital Management Inc. Cuts Stake in Wyndham Hotels & Resorts, Inc. (NYSE:WH) - Defense World
Vaccinex secures $6.2 million through warrant exercises By Investing.com - Investing.com Canada
What's Going On With Vaccinex Stock Wednesday? - Benzinga
Vaccinex Inc (VCNX) 財務データ
収益
当期純利益
現金流量
EPS
Vaccinex Inc (VCNX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FRIEDBERG ALBERT | Director |
Sep 18 '24 |
Option Exercise |
5.64 |
240,009 |
1,352,691 |
1,020,633 |
| FRIEDBERG ALBERT | Director |
Aug 09 '24 |
Buy |
4.51 |
100 |
451 |
780,624 |
| FRIEDBERG ALBERT | Director |
Aug 05 '24 |
Buy |
4.60 |
3,653 |
16,804 |
777,771 |
| FRIEDBERG ALBERT | Director |
Aug 06 '24 |
Buy |
4.92 |
2,753 |
13,545 |
780,524 |
| FRIEDBERG ALBERT | Director |
Aug 01 '24 |
Buy |
4.72 |
11,703 |
55,238 |
774,118 |
| FRIEDBERG ALBERT | Director |
Jul 31 '24 |
Buy |
6.15 |
200,000 |
1,230,280 |
762,415 |
| FRIEDBERG ALBERT | Director |
May 29 '24 |
Buy |
4.95 |
957 |
4,737 |
561,554 |
| FRIEDBERG ALBERT | Director |
May 30 '24 |
Buy |
5.20 |
861 |
4,473 |
562,415 |
| FRIEDBERG ALBERT | Director |
Apr 19 '24 |
Buy |
4.73 |
282 |
1,334 |
560,597 |
| Van Strydonck, Gerald E. | Director |
Dec 26 '23 |
Sale |
0.72 |
3,149 |
2,267 |
0 |
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):